New antibody shot shows promise for HIV control in early trial
NCT ID NCT05890963
First seen Apr 28, 2026 · Last updated Apr 28, 2026
Summary
This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on treatment. The goal is to check safety and see if the antibody can lower the amount of virus in the blood. Results will help design future studies for both HIV prevention and treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute for Medical Research-Mbeya Medical Resarch Center
Mbeya, Tanzania
Conditions
Explore the condition pages connected to this study.